Bayer (FRA:BAYN) Shares Pass Above 200 Day Moving Average of $62.34

Bayer AG (FRA:BAYN)’s share price passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $62.34 and traded as high as $69.42. Bayer shares last traded at $69.32, with a volume of 2,439,508 shares.

A number of equities analysts recently commented on BAYN shares. JPMorgan Chase & Co. set a €69.00 ($80.23) price objective on Bayer and gave the stock a “neutral” rating in a research note on Monday, November 18th. Warburg Research set a €61.00 ($70.93) price objective on Bayer and gave the stock a “neutral” rating in a research note on Monday, October 7th. Independent Research set a €61.00 ($70.93) price objective on Bayer and gave the stock a “sell” rating in a research note on Thursday, October 31st. Deutsche Bank set a €70.00 ($81.40) price objective on Bayer and gave the stock a “neutral” rating in a research note on Thursday, October 31st. Finally, HSBC set a €63.00 ($73.26) price objective on Bayer and gave the stock a “neutral” rating in a research note on Wednesday, November 27th. One analyst has rated the stock with a sell rating, nine have given a hold rating and eight have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of €78.47 ($91.24).

The company has a 50 day simple moving average of €68.52 and a 200-day simple moving average of €62.34.

Bayer Company Profile (FRA:BAYN)

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Featured Article: How big is the FinTech market?

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.